Alik Farber, MD
James Utley Professor and Chair of Surgery
Boston University Chobanian & Avedisian School of Medicine

MD, Harvard Medical School
MBA, Brandeis University
BS, Brown University



Alik Farber, MD, MBA, is interim Chair of the Departments of Surgery and Radiology at the Boston University Chobanian & Avedisian School of Medicine. Dr. Farber is also interim Chief of the Department of Surgery at Boston Medical Center, where he is Associate Chief Medical Officer for Surgical Services and Chief of the Division of Vascular & Endovascular Surgery.

After earning his undergraduate degree from Brown University, Dr. Farber received his medical degree from Harvard Medical School. He completed residency in general surgery at Massachusetts General Hospital, a vascular surgery fellowship at Dartmouth-Hitchcock Medical Center, and an endovascular surgery fellowship at Southern Illinois School of Medicine. He received an MBA from the Heller School for Social Policy and Management at Brandeis University.

Dr. Farber began his career in 1999 as a vascular surgeon in private practice at Cedars-Sinai Medical Center in Los Angeles. In 2005, he was recruited to Boston Medical Center as an attending vascular surgeon and joined the faculty of the Chobanian & Avedisian School of Medicine as an Assistant Professor, rising to full Professor in 2015. Throughout his tenure, Dr. Farber has been involved in diverse academic, clinical operational, and leadership roles.

Dr. Farber’s clinical practice focuses on peripheral artery disease. An internationally recognized authority on limb ischemia, he has been invited to contribute to multidisciplinary consensus statements and has lectured across the world on this topic. Dr. Farber has served as principal investigator (PI) for multiple clinical trials involving wound care, intermittent claudication, and deep-vein arterialization. Most recently he served as co-PI of the landmark Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) trial. Funded by the National Heart, Lung, and Blood Institute, this international, multicenter, randomized controlled trial compared traditional bypass surgery with endovascular treatment for patients with chronic limb threatening ischemia. More than 1,800 patients at 150 sites across North America, Europe, and New Zealand were enrolled, with results published in The New England Journal of Medicine in 2022. Dr. Farber, who chairs the BEST-CLI Publications Committee, continues to be actively involved in trial dataset analysis and research dissemination through the BEST-CLI Collaborative, funded by the Novo Nordisk Foundation.

A fellow of the American College of Surgeons and a distinguished fellow of the Society of Vascular Surgery, Dr. Farber frequently serves in leadership roles for professional organizations. Currently, he is Secretary of the Society for Clinical Vascular Surgery and Treasurer of both the New England Society for Vascular Surgery and the Massachusetts Chapter of the American College of Surgeons.

Dr. Farber has authored more than 260 peer-reviewed manuscripts and 30 book chapters, and has edited two textbooks. He has given more than 160 presentations in over 20 countries.

Surgeon-in-Chief
Boston Medical Center


Professor
Boston University Chobanian & Avedisian School of Medicine
Surgery
Vascular and Endovascular Surgery

Associate Chief Medical Officer for Surgical Services
Boston Medical Center


Section Chief
Boston University Chobanian & Avedisian School of Medicine
Surgery
Vascular and Endovascular Surgery

Professor
Boston University Chobanian & Avedisian School of Medicine
Radiology
Vascular & Interventional

Member
Boston University
Evans Center for Interdisciplinary Biomedical Research




A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols
05/01/2012 - 12/31/2015 (PI)
Grifols Inc.


A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm^2 to <= 36 cm^2
10/15/2013 - 08/30/2015 (PI)
HealthPoint Limited


A Non-Interventional Safety Study Providing 12 Months Follow-Up from First Exposure to HP802-247 in Subjects with Venous Leg Ulcer
05/01/2012 - 04/30/2015 (PI)
HealthPoint Limited


Observational Study of Tissue Plasminogen Activator Used for Catheter Directed Thrombolysis in Patients with Acute Lower Extremety Native Artery or Bypass Graft Occlusion
01/27/2014 - 01/26/2015 (PI)
Grifols Inc.


A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers
05/01/2012 - 04/30/2014 (PI)
HealthPoint Limited


Vital Access Venous Window Needle Guide for salvage of AV Fistulae (SAVE) Trial
08/15/2012 - 08/14/2013 (PI)
Vital Access Corp


IN-BALANCE VLU (Inflammation, Bacteria, and Angiogenesis effects in launching venous leg ulcer healing: a clinical evaluation)
08/01/2012 - 07/31/2013 (PI)
Celleration, Inc.


A Phase 2 randomized open label study to evaluate the effects of different intra-thrombus infusion regiments of plasmin humun compared to placebo
08/01/2011 - 07/31/2012 (PI)
Talecris Pharmaceuticals


A Phase 2 randomized open label study to evaluate the effects of different intra-thrombus infusion regiments of plasmin humun compared to placebo
08/01/2011 - 07/31/2012 (PI)
Talecris Pharmaceuticals


A Phase II Randomized, Double Blind, Placebo Controlled Dose Finding Study Investigating the Efficacy of HP802-247 in Venous Leg Ulcers
08/01/2009 - 12/31/2011 (PI)
HealthPoint Limited


Showing 10 of 16 results. Show All Results

LF-CA-PR-53-PROMISE III Trial
12/09/2022 - 12/09/2025 (PI)
LimFlow Inc

Assessment of Wound Closure Comparing Synthetic Hybrid- Scale Fiber Matrix with Lyophilized Acellular Fish Skin in Treating Diabetic Foot Ulcers (DFU) and with Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)
10/12/2022 - 10/12/2025 (PI)
Acera Surgical Inc.

Best Endovascular vs. Best Surgical Therapy in Patients with Critical Limb Ischemia (Best-CLI)
09/01/2022 - 08/31/2025 (Subcontract PI)
PI: Alik Farber, MD
Brigham and Womens Hospital Novo Nordisk Fdn

A multi-center prospective study to evaluate the safety and effectiveness of the VasQ external suppo
11/01/2017 - 01/31/2025 (PI)
Laminate Medical Technologies Inc.

Novonordisk-NN9535-4533
09/14/2021 - 09/14/2024 (PI)
Novo Nordisk

A comparative evaluation of a marine polysaccharide dressing and a carboxymethylcellulose dressing on subjects with lower extremity venous ulcerss
10/14/2020 - 10/14/2023 (PI)
Medline Industries LLC

Natural Progression of High-Risk Chronic Limb-Threatening Ischemia. The CLariTI Study.
03/25/2021 - 08/31/2023 (PI)
LimFlow Inc

A multicenter, prospective, randomized, placebo controlled, double blind study performed to…
09/24/2019 - 08/31/2023 (PI)
MediWound Ltd.

A multicenter retrospective observational study to evaluate primary patency of arteriovenous fistulae 6 months post-surgery.
11/23/2020 - 04/30/2023 (PI)
Laminate Medical Technologies Inc.

BEST-CLI Trial-CCC-Lead
09/17/2013 - 03/31/2023 (Multi-PI)
PI: Alik Farber, MD
Brigham and Womens Hospital NIH NHLBI
1U01HL107352-01A1

Showing 10 of 19 results. Show All Results

Title


Yr Title Project-Sub Proj Pubs
2024 Role of Intravenous ultrasound (IVUS) in arteriovenous hemodialysis access dysfunction 1R01DK141016-01
2018 BEST-CLI Trial-CCC-Lead 5U01HL107352-05 4
2017 BEST-CLI Trial-CCC-Lead 5U01HL107352-04 4
2016 BEST-CLI Trial-CCC-Lead 4U01HL107352-03 4
2015 BEST-CLI Trial-CCC-Lead 5U01HL107352-02 4
2013 BEST-CLI Trial-CCC-Lead 1U01HL107352-01A1 4

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Menard MT, Farber A, Doros G, McGinigle KL, Chisci E, Clavijo LC, Kayssi A, Schneider PA, Hawkins BM, Dake MD, Hamza T, Strong MB, Rosenfield K, Conte MS. The impact of revascularization strategy on clinical failure, hemodynamic failure, and chronic limb-threatening ischemia symptoms in the BEST-CLI Trial. J Vasc Surg. 2024 Jul 26.View Related Profiles. PMID: 39069016
     
  2. Zhu M, Farber A, King E, Alonso A, Kobzeva-Herzog A, Cooper J, Lotfollahzadeh S, Chitalia VC, Siracuse JJ. Early Kidney Transplantation or Conversion to Peritoneal Dialysis after First-Time Arteriovenous Access Creation. Ann Vasc Surg. 2024 Nov; 108:57-64.View Related Profiles. PMID: 38942372
     
  3. Venermo MA, Farber A, Schanzer A, Menard MT, Rosenfield K, Dosluoglu H, Goodney PP, Abou-Zamzam AM, Motaganahalli R, Doros G, Creager MA. Reduction of Major Amputations after Surgery versus Endovascular Intervention: The BEST-CLI Randomised Trial. Eur J Vasc Endovasc Surg. 2024 Jun 24.View Related Profiles. PMID: 38925339
     
  4. Heindel P, Fitzgibbon JJ, McKie K, Goudreau B, Dieffenbach BV, Aicher BO, Belkin M, Farber A, Menard MT, Hussain MA. Real-World Vein Mapping Practice Patterns Before Endovascular Treatment of Limb Ischemia. J Surg Res. 2024 Sep; 301:62-70. PMID: 38917575; PMCID: PMC11427167; DOI: 10.1016/j.jss.2024.05.011;
     
  5. Koh DJ, Eslami MH, Sung E, Seo HH, Lin B, Lin A, Cheng TW, Alonso A, King E, Farber A, Siracuse JJ. Medicare billing and utilization trends in vascular surgery. J Vasc Surg. 2024 Oct; 80(4):1260-1268.e1.View Related Profiles. PMID: 38909918
     
  6. Giles KA, Farber A, Menard MT, Conte MS, Nolan BW, Siracuse JJ, Strong MB, Doros G, Venermo M, Azene E, Rosenfield K, Powell RJ. Surgery or endovascular therapy for patients with chronic limb-threatening ischemia requiring infrapopliteal interventions. J Vasc Surg. 2024 Nov; 80(5):1515-1524.View Related Profiles. PMID: 38908805
     
  7. Alonso A, Kobzeva-Herzog AJ, Yahn C, Farber A, King EG, Hicks C, Eslami MH, Patel VI, Rybin D, Siracuse JJ. Higher stroke risk after carotid endarterectomy and transcarotid artery revascularization is associated with relative surgeon volume ratio. J Vasc Surg. 2024 Oct; 80(4):1097-1103.View Related Profiles. PMID: 38906430
     
  8. Cheng TW, Farber A. Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia. Adv Surg. 2024 Sep; 58(1):121-133. PMID: 39089772
     
  9. Chugh PV, Danford J, Farber A, Ayalon N, Verma A, Helm RH, Monahan KM, Kalish JA. Retrieval of Embolized WATCHMAN® Flex Atrial Appendage Occlusion Device. Vasc Endovascular Surg. 2024 Oct; 58(7):752-756.View Related Profiles. PMID: 38747057; DOI: 10.1177/15385744241251657;
     
  10. Boelitz KM, Forsyth A, Crawford A, Simons JP, Siracuse JJ, Farber A, Hamburg N, Eberhardt R, Schanzer A, Jones DW. Polyvascular disease is common in patients undergoing carotid endarterectomy and lower extremity bypass and is associated with worse outcomes. J Vasc Surg. 2024 Oct; 80(4):1149-1158.e2.View Related Profiles. PMID: 38723911
     
Showing 10 of 366 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 363 publications over 26 distinct years, with a maximum of 41 publications in 2016

YearPublications
19921
19931
19992
20011
20022
20033
20044
20051
20073
20082
20096
20104
201112
20129
201319
201415
201521
201641
201738
201840
201925
202036
202119
202214
202323
202421

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
Contact for Mentoring:

85 E. Concord St.
Boston MA 02118
Google Map


Farber's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_